medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2016-2-36-41medsovet-37Research ArticleБеременность и родыPregnancy and childbirthЖелезодефицитная анемия у беременных и родильниц - выбор препаратов для леченияIron deficiency anemia in pregnant and postpartum women - choosing drugs for treatmentДубровинаН. В.DubrovinaN. V.noemail@neicon.ruТютюнникВ. Л.TyutyunnikV. L.noemail@neicon.ruКанН. Е.KanN. E.noemail@neicon.ruДокуеваР. С.DokuyevaR. S.noemail@neicon.ruНаучный центр акушерства, гинекологии и перинатологии им. акад. В.И. КулаковаРоссияScientific Center for Obstetrics, Gynecology and Perinatology named after acad. KulakovRussian Federation201630122016023641Copyright © Дубровина Н.В., Тютюнник В.Л., Кан Н.Е., Докуева Р.С., 20162016Дубровина Н.В., Тютюнник В.Л., Кан Н.Е., Докуева Р.С.Dubrovina N.V., Tyutyunnik V.L., Kan N.E., Dokuyeva R.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/37

Железодефицитная анемия является широко распространенным заболеванием. По различным данным, она встречается у большинства женщин репродуктивного возраста, беременных и родильниц. Это связано с высокими потребностями в железе во время гестации и повышенным его расходом в послеродовом периоде. Выбор наиболее эффективного железозаместительного препарата, действие которого будет реализоваться в максимально короткие сроки, лежит в основе оптимального решения данной проблемы и способствует благоприятным исходам.

Iron deficiency anemia is a common disease. According to various reports, it is found in the majority of women of childbearing age, pregnant and postpartum women. This is due to the high requirement of iron during gestation and increased consumption in the postpartum period. Choosing the most effective iron replacement drug the effect of which is realized within the minimum period of time could be the best solution of the problem and contribute to favorable outcomes.

беременностьпослеродовый периоджелезодефицитная анемияпарентеральные препараты железакарбоксимальтозат железаpregnancypostpartum periodiron deficiency anemiaparenteral iron preparationsferric carboxymaltoseReferencesЧушков Ю.В. Современные возможности коррекции дефицита железа в акушерстве и гинекологии. Гинекология, 2011(6): 44-47.Чушков Ю.В. Современные возможности коррекции дефицита железа в акушерстве и гинекологии. Гинекология, 2011(6): 44-47.Серов В.Н., Бурлев В.А., Коноводова Е.Н. и др. Диагностика, профилактика и лечение желе-зодефицитных состояний у беременных и родильниц (клинический протокол). Акушерство и гинекология, 2014., 3: 11-17.Серов В.Н., Бурлев В.А., Коноводова Е.Н. и др. Диагностика, профилактика и лечение желе-зодефицитных состояний у беременных и родильниц (клинический протокол). Акушерство и гинекология, 2014., 3: 11-17.World Health Organization. Guideline: daily iron and folic acid supplementation in pregnant women. Электронный доступ: http//apps.who.int/iris/bitstram/10665/77770/1/9789241501996_eng.pdfWorld Health Organization. Guideline: daily iron and folic acid supplementation in pregnant women. Электронный доступ: http//apps.who.int/iris/bitstram/10665/77770/1/9789241501996_eng.pdfЗапорожец Э.Е., Шувалова М.П., Цымлякова Л.М. и соавт. Основные показатели деятельности службы охраны здоровья матери и ребенка в Российской Федерации. М., 2013. 102с.Запорожец Э.Е., Шувалова М.П., Цымлякова Л.М. и соавт. Основные показатели деятельности службы охраны здоровья матери и ребенка в Российской Федерации. М., 2013. 102с.Серов В.Н., Бурлев В.А., Коноводова Е.Н. и др. Лечение манифестного дефицита железа у беременных и родильниц (медицинская технология). Разрешение (серия АА №0000151) федеральной службы по надзору в сфере здравоохранения и социального развития на применение новой медицинской технологии ФС №2010/003 от 18.01.2010 г. М.: МедЭкспертПресс, 2010- 28с.Серов В.Н., Бурлев В.А., Коноводова Е.Н. и др. Лечение манифестного дефицита железа у беременных и родильниц (медицинская технология). Разрешение (серия АА №0000151) федеральной службы по надзору в сфере здравоохранения и социального развития на применение новой медицинской технологии ФС №2010/003 от 18.01.2010 г. М.: МедЭкспертПресс, 2010- 28с.MiLman N. Postpartum anemia: definition, prevalence, causes, and consequences. Ann Hematol, 2011, 28: 7-15.MiLman N. Postpartum anemia: definition, prevalence, causes, and consequences. Ann Hematol, 2011, 28: 7-15.Breymann C, Honegger C, HoLzgreve W, Surbek D. Diagnosis and treatment of iron-deficiency anaemia during pregnancy and postpartum. Arch. Gynecol. Obstet., 2010, 282 (5): 577-80.Breymann C, Honegger C, HoLzgreve W, Surbek D. Diagnosis and treatment of iron-deficiency anaemia during pregnancy and postpartum. Arch. Gynecol. Obstet., 2010, 282 (5): 577-80.World Health Organization. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Vitamin and mineral nutrition information system. Электронный доступ: http//www.who.int/iris/bitstream/ 10665/85839/http//apps.who.int//iris/bit-stream/10665/85839/3/WHO_NMH_NHD_ MNM_11.1_eng.pdf?ua=1.World Health Organization. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Vitamin and mineral nutrition information system. Электронный доступ: http//www.who.int/iris/bitstream/ 10665/85839/http//apps.who.int//iris/bit-stream/10665/85839/3/WHO_NMH_NHD_ MNM_11.1_eng.pdf?ua=1.Vandevijvere S, Amsalkhir S, Oyen HV et al. Iron status and its determinants in a nationaLLy representative sample of pregnant women. J. Acad. Nutr. Diet., 2013, 23: 2212-2672.Vandevijvere S, Amsalkhir S, Oyen HV et al. Iron status and its determinants in a nationaLLy representative sample of pregnant women. J. Acad. Nutr. Diet., 2013, 23: 2212-2672.Krafft A, Bencaiova G, Breymann C. Selective use of recombinant human erythropoietin in pregnant patients with severe anemia or non-responsive to iron sucrose alone. Fetal. Diagn. Ther., 2009, 25(2): 239-45.Krafft A, Bencaiova G, Breymann C. Selective use of recombinant human erythropoietin in pregnant patients with severe anemia or non-responsive to iron sucrose alone. Fetal. Diagn. Ther., 2009, 25(2): 239-45.Kozuki N, Lee AC, Katz J. Child Health Epidemiology Reference Group. Moderate to severe, but not mild, maternal anemia is associated with increased risk of small-for-gestation-al-age outcomes. J. Nutr., 2012, 142(2): 358-62.Kozuki N, Lee AC, Katz J. Child Health Epidemiology Reference Group. Moderate to severe, but not mild, maternal anemia is associated with increased risk of small-for-gestation-al-age outcomes. J. Nutr., 2012, 142(2): 358-62.Arija V, Ribot B, Aranda N. Prevalence of iron deficiency states and risk of haemoconcentra-tion during pregnancy according to initial iron stores and iron supplementation. Public Health Nutr., 2013, 11: 1-8.Arija V, Ribot B, Aranda N. Prevalence of iron deficiency states and risk of haemoconcentra-tion during pregnancy according to initial iron stores and iron supplementation. Public Health Nutr., 2013, 11: 1-8.Ren A, Wang J, Ye RW et al. Low first-trimester hemoglobin and low birth weight, preterm birth and small for gestational age newborns. Int J Gynaecol Obstet., 2007, 98(2): 124-28.Ren A, Wang J, Ye RW et al. Low first-trimester hemoglobin and low birth weight, preterm birth and small for gestational age newborns. Int J Gynaecol Obstet., 2007, 98(2): 124-28.Beard JL, Hendricks MK, Perez EM et al. Maternal iron deficiency anemia affects postpartum emotions and cognition. J Nutr., 2005, 135(2): 267-72. Neeru S, Nair NS, Rai L. Iron sucrose versus oral iron therapy in pregnancy anemia. Indian J Community Med., 2012, 37(4): 214-8. Khalafallah AA, Dennis AE, Ogden K et al. Three-year follow-up of a randomised clinical trial of intravenous versus oral iron for anaemia in pregnancy. BMJ Open, 2012, 18: 2-5.Beard JL, Hendricks MK, Perez EM et al. Maternal iron deficiency anemia affects postpartum emotions and cognition. J Nutr., 2005, 135(2): 267-72. Neeru S, Nair NS, Rai L. Iron sucrose versus oral iron therapy in pregnancy anemia. Indian J Community Med., 2012, 37(4): 214-8. Khalafallah AA, Dennis AE, Ogden K et al. Three-year follow-up of a randomised clinical trial of intravenous versus oral iron for anaemia in pregnancy. BMJ Open, 2012, 18: 2-5.Kochhar PK, Kaundal A, Ghosh P. Intravenous iron sucrose versus oral iron in treatment of iron deficiency anemia in pregnancy: A randomized clinical trial. J. Obstet. Gynaecol. Res., 2012, 26: 1-7,Kochhar PK, Kaundal A, Ghosh P. Intravenous iron sucrose versus oral iron in treatment of iron deficiency anemia in pregnancy: A randomized clinical trial. J. Obstet. Gynaecol. Res., 2012, 26: 1-7,Auerbach M, Ballard H. Clinical use of intravenous iron: administration, efficacy, and safety. Hematology Am. Soc. Hematol. Educ. Program. 2010; 2010 (1), 338-47.Auerbach M, Ballard H. Clinical use of intravenous iron: administration, efficacy, and safety. Hematology Am. Soc. Hematol. Educ. Program. 2010; 2010 (1), 338-47.Tariq N, Ayub R, Khan WU et al. Parenteral iron therapy in the treatment of iron deficiency anemia during pregnancy: a randomized controlled trial. J Coll Physicians Surg Pak, 2015, 25(3): 193-7.Tariq N, Ayub R, Khan WU et al. Parenteral iron therapy in the treatment of iron deficiency anemia during pregnancy: a randomized controlled trial. J Coll Physicians Surg Pak, 2015, 25(3): 193-7.Balle GR, Clark JA, Lane CE, Lane PL. Hypersensitivity reactions and deaths assosia-tied with intravenous iron preparations. Nephrol Dial Transplant, 2005, 20: 1443-49.Balle GR, Clark JA, Lane CE, Lane PL. Hypersensitivity reactions and deaths assosia-tied with intravenous iron preparations. Nephrol Dial Transplant, 2005, 20: 1443-49.Шалина Р.И., Кутакова Ю.Ю., Бреусенко Л.И. и др. Оценка эффективности применения препарата Венофер при железодефицитных состояниях после акушерских кровотечений. Вопросы гинекологии, акушерства и перина-тологии, 2004, 1 (3): 37-42.Шалина Р.И., Кутакова Ю.Ю., Бреусенко Л.И. и др. Оценка эффективности применения препарата Венофер при железодефицитных состояниях после акушерских кровотечений. Вопросы гинекологии, акушерства и перина-тологии, 2004, 1 (3): 37-42.Моисеев С.В. Железа карбоксимальтозат (Феринжект®) - новый внутривенный препарат для лечения железодефицитной анемии. Клиническая фармакология и терапия, 2012, 21 (2): 2-7Моисеев С.В. Железа карбоксимальтозат (Феринжект®) - новый внутривенный препарат для лечения железодефицитной анемии. Клиническая фармакология и терапия, 2012, 21 (2): 2-7Keating GM. Ferric carboxymaltose: a review of its use in iron deficiency. Drugs, 2015, 75(1):101-27Keating GM. Ferric carboxymaltose: a review of its use in iron deficiency. Drugs, 2015, 75(1):101-27Seid M, Derman RJ, Baker JB et al. Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial. Am. J. Obstet. Gynecol., 2008, 199(4): 431-37.Seid M, Derman RJ, Baker JB et al. Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial. Am. J. Obstet. Gynecol., 2008, 199(4): 431-37.Van Wyck D, Martens MG, Seid MH et al. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Obstet. Gynecol., 2007, 110 (2 Pt. 1): 267-78.Van Wyck D, Martens MG, Seid MH et al. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Obstet. Gynecol., 2007, 110 (2 Pt. 1): 267-78.Froessler B, Collingwood J, Hodyl NA, Dekker G. Intravenous ferric carboxymaltose for anaemia in pregnancy. BMC Pregnancy Childbirth, 2014, 14: 115.Froessler B, Collingwood J, Hodyl NA, Dekker G. Intravenous ferric carboxymaltose for anaemia in pregnancy. BMC Pregnancy Childbirth, 2014, 14: 115.Christoph P, Schuller C, Studer H et al. Intravenous iron treatment in pregnancy: comparison of high-dose ferric carboxymaltose vs. iron sucrose. J Perinat Med., 2012, 40(5): 469-74.Christoph P, Schuller C, Studer H et al. Intravenous iron treatment in pregnancy: comparison of high-dose ferric carboxymaltose vs. iron sucrose. J Perinat Med., 2012, 40(5): 469-74.Breymann C, Gliga F, Bejenariu C, Strizhova N. Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of post-partum iron deficiency anemia. Int. J Gynaecol Obstet, 2008, 101(1): 67-73.Breymann C, Gliga F, Bejenariu C, Strizhova N. Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of post-partum iron deficiency anemia. Int. J Gynaecol Obstet, 2008, 101(1): 67-73.Chushkov Y.V. Current options for correction of iron deficiency in obstetrics and gynecology. Ginekologiya, 2011, 6: 44-47.Chushkov Y.V. Current options for correction of iron deficiency in obstetrics and gynecology. Ginekologiya, 2011, 6: 44-47.Serov V.N., Burlev V.A., Konovodova E.N. et al. Diagnosis, prevention and treatment of iron deficiency in pregnant and postpartum women (clinical protocol). Akusherstvo i Ginekologiya, 2014, 3: 11-17.Serov V.N., Burlev V.A., Konovodova E.N. et al. Diagnosis, prevention and treatment of iron deficiency in pregnant and postpartum women (clinical protocol). Akusherstvo i Ginekologiya, 2014, 3: 11-17.World Health Organization. Guideline: daily iron and folic acid supplementation in pregnant women. Electronic access: http://apps.who.int/iris/bitstream/10665/77770/1/9789241501996_eng.pdf.World Health Organization. Guideline: daily iron and folic acid supplementation in pregnant women. Electronic access: http://apps.who.int/iris/bitstream/10665/77770/1/9789241501996_eng.pdf.Zaporozhets E.E., Shuvalova M.P., Tsymlyakova L.M. et al. Key performance indicators for maternal and child health service in the Russian Federation. M., 2013. 102p.Zaporozhets E.E., Shuvalova M.P., Tsymlyakova L.M. et al. Key performance indicators for maternal and child health service in the Russian Federation. M., 2013. 102p.Serov V.N., Burlev V.A., Konovodova E.N. et al. Management of overt iron deficiency in pregnant and postpartum women (medical technology). // Authorisation (series AA №0000151) of the Federal Service on Surveillance in Healthcare and Social Development for the use of new medical technology FS №2010/003 of 18.01.2010. M.: MedEkspertPress, 2010.- 28p.Serov V.N., Burlev V.A., Konovodova E.N. et al. Management of overt iron deficiency in pregnant and postpartum women (medical technology). // Authorisation (series AA №0000151) of the Federal Service on Surveillance in Healthcare and Social Development for the use of new medical technology FS №2010/003 of 18.01.2010. M.: MedEkspertPress, 2010.- 28p.Shalina R.I., Kutakova Y.Y., Breusenko L.I. et al. Evaluating the effectiveness of Venofer in iron deficiency states after obstetric hemorrhage. Voprosy Ginekologii, Akusherstva i Perinatologii, 2004, 1 (3): 37-42.Shalina R.I., Kutakova Y.Y., Breusenko L.I. et al. Evaluating the effectiveness of Venofer in iron deficiency states after obstetric hemorrhage. Voprosy Ginekologii, Akusherstva i Perinatologii, 2004, 1 (3): 37-42.Moiseyev S.V. Ferric carboxymaltose (Ferinject®) is a new intravenous drug for the treatment of iron deficiency anemia. Klinicheskaya Farmakologiya i Terapiya, 2012, 21(2): 2-7.Moiseyev S.V. Ferric carboxymaltose (Ferinject®) is a new intravenous drug for the treatment of iron deficiency anemia. Klinicheskaya Farmakologiya i Terapiya, 2012, 21(2): 2-7.

The authors declare that there are no conflicts of interest present.